Articles related to TRANSPLANT MEDICINE

In light of recent findings, CD24Fc emerges as a potential game-changer in preventing acute GVHD in HSCT patients, with a notable survival rate improvement to 96.2% for severe cases.

Recent studies have highlighted the effectiveness of ruxolitinib in managing steroid-refractory chronic graft-vs-host disease, showcasing a significant improvement in overall response rates and failure-free survival compared to standard therapies.

In a landmark surgical endeavor, neurosurgeons have transferred sciatic nerve components from an amputated foot to the brachial plexus, showcasing the potential of neuroplasticity in restoring hand mobility.

The Organ Transplant and Procurement Network (OTPN) is set to undergo modernization and improvement after being criticized for lack of transparency, long waits, mishandling of organs, and the number of people who die on the waitlist each year. The Health Resources and Services Administration (HRSA) has launched the OTPN modernization project, which will focus on accountability. The current system is outdated and has been responsible for 70 deaths between 2010 and 2020, according to a 2022 senate report. The HRSA plans to take steps, such as creating a new dashboard, to provide transparency and better serve patients and their families. Additional modernization will focus on overhauling the operations of the OTPN system to ensure higher compliance and a greater focus on patient safety. Organ transplants and the OTPN disproportionately affect the Black community in the US. About 30% of the ONTP waitlist is Black Americans, and about 90% are waiting for kidney transplants. The HRSA’s plan hopes to address the inequality by improving accountability, transparency, and systems of organ retrieval and matching. The changes will benefit patients, and physicians might be able to see more of their patients receive the life-saving transplants they need.

The findings of this randomized clinical trial support the notion that, despite improved DFS, patients 60 years or younger with intermediate-risk AML, as defined by Medical Research Council cytogenetic criteria, do not benefit from allo-HCT during first CR in terms of OS. Early identification of a suitable donor allows for the timely rescue of patients who have relapsed following conventional consolidation chemotherapy. Future research that uses longitudinal monitoring of residual disease dynamics will aid in personalizing the optimal time point for allo-HCT in the majority of patients.

This 62-year-old man had a lung transplant 3 years previously for IPF and is on tacrolimus, mycophenolate, and prednisone. Which therapy is most appropriate for their zoster outbreak? IV acyclovir Oral famciclovir Oral valacyclovir Herpes zoster vaccine